Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential

This grant supports activities advancing the development of new small molecule antiviral therapeutics for emerging or re-emerging viral infections with epidemic or pandemic potential. The goal is to better prepare Europe and the world for future health threats by providing experimental antivirals for clinical investigation and patient treatment, strengthening research and innovation in the EU, and supporting the European Medical Countermeasures Strategy. The grant encourages the participation of start-ups and SMEs and requires close engagement with regulatory bodies. Projects must target specific viruses or groups of viruses and may include drug discovery, optimisation, in vitro and in vivo studies, manufacturing under GMP, and early clinical trials. Antibodies and antibody-derived proteins are excluded.

AgencyHORIZON (EU)
RegionEU
CountryN/A
Legal formCompany, NGO, Government organization, Other
Start date10 Feb 2027
End date13 Apr 2027
Max funding€9,000,000–€11,000,000 per grant
Budget€44,200,000 overall budget allocated to this topic for 2027
Coverage

EU funding for eligible costs as per Horizon Europe terms. US legal entities are eligible for funding. Funding rules follow Horizon Europe Model Grant Agreement.

Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential • EUGrants.AI